A brief review of the latest science on breathing and the brain, and overall health, serves as a reminder that breathing deserves much closer attention – there’s more going on with each breath than we realize.
University of Cambridge researchers report making eye contact with a baby causes brainwave synchronization in both the child and person they are looking at. Researchers believe this synchronization can help boost communication and learning skills.
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight.
Codiak intends to use the proceeds of the Series C financing to advance its initial product candidates into clinical trials, and to continue to develop the company's transformational exosome therapeutic platform.
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections in a population.
In a recently published paper, researchers outline the importance of REM sleep and the causes and consequences of loss of REM sleep.
Investigators at The Feinstein Institute for Medical Research discovered dozens of new genetic variations associated with a person’s general cognitive ability. The findings, which were published online today in Cell Reports, have the potential to help researchers develop more targeted treatment for cognitive and memory disorders.
A recent study analyzed population-based data to determine the global causes of blindness and visual impairment and made projections by cause to 2020.
Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).
It may be possible to use drugs that are already in development to overcome radiotherapy resistance in tumors, which is often a major barrier to the successful treatment of many cancers.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.